SIGN UP
LOG IN
News
Innovent Biologics
--
--
0.00%
Weekly Report: what happened at Innovent Biologics last week (0623-0627)?
Weekly Report · 1d ago
INNOVENT ANNOUNCES THE PHASE 3 CLINICAL STUDY DREAMS-1 OF MAZDUTIDE IN CHINA WERE ORALLY PRESENTED AT ADA 85TH SCIENTIFIC SESSIONS
Reuters · 6d ago
Weekly Report: what happened at Innovent Biologics last week (0616-0620)?
Weekly Report · 06/22 22:01
Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
PR Newswire · 06/22 01:35
It Looks Like The CEO Of Innovent Biologics, Inc. (HKG:1801) May Be Underpaid Compared To Peers
Simply Wall St · 06/18 23:02
High Growth Tech Stocks in Asia Featuring 3 Promising Picks
Simply Wall St · 06/17 04:08
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
PR Newswire · 06/16 00:00
Weekly Report: what happened at Innovent Biologics last week (0609-0613)?
Weekly Report · 06/15 22:01
BUZZ-Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says
Reuters · 06/11 06:39
Weekly Report: what happened at Innovent Biologics last week (0602-0606)?
Weekly Report · 06/08 22:01
INNOVENT'S IBI363 (PD-1/IL-2Α-BIAS BISPECIFIC ANTIBODY FUSION PROTEIN) RECEIVES SECOND NMPA BREAKTHROUGH THERAPY DESIGNATION FOR IMMUNO-RESISTANT SQUAMOUS NON-SMALL CELL LUNG CANCER
Reuters · 06/05 00:23
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
PR Newswire · 06/05 00:00
Asian Market: Discovering 3 Stocks That May Be Trading Below Their Estimated Value
Simply Wall St · 06/03 04:07
2025 ASCO ORAL PRESENTATION: INNOVENT BIOLOGICS ANNOUNCES UPDATED DATE OF IBI363 (FIRST-IN-CLASS PD-1/IL-2Α-BIAS BISPECIFIC ANTIBODY FUSION PROTEIN) FROM PHASE 1 CLINICAL STUDIES IN ADVANCED COLORECTAL CANCER
Reuters · 06/02 00:00
Weekly Report: what happened at Innovent Biologics last week (0526-0530)?
Weekly Report · 06/01 22:01
ASCO 2025 ORAL PRESENTATION: INNOVENT BIOLOGICS ANNOUNCES UPDATED DATA OF IBI363 (FIRST-IN-CLASS PD-1/IL-2Α -BIAS BISPECIFIC ANTIBODY FUSION PROTEIN) FROM PHASE 1 AND 2 CLINICAL STUDIES ON IMMUNOTHERAPY-TREATED ADVANCED MALIGNANT MELANOMA
Reuters · 06/01 01:39
INNOVENT ANNOUNCES A PHASE 3 STUDY OF PICANKIBART (ANTI-IL-23P19 ANTIBODY) COMPLETES FIRST PARTICIPANT DOSING, EXPLORING BIOLOGICS SWITCHING TREATMENT FOR PSORIASIS PATIENTS WITH PRIOR INADEQUATE RESPONSE TO ANTI-IL-17 ANTIBODIES
Reuters · 05/29 01:33
Weekly Report: what happened at Innovent Biologics last week (0519-0523)?
Weekly Report · 05/25 22:01
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation
PR Newswire · 05/19 00:00
Weekly Report: what happened at Innovent Biologics last week (0512-0516)?
Weekly Report · 05/18 22:01
About Innovent Biologics
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sale of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly operates in the domestic and overseas markets.
MoreRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.